Clinical Trial Update: Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of vemurafenib and copanlisib in radioiodine-refractory thyroid cancers has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Thyroid Cancer
• Papillary Thyroid Cancer
• Thyroid Cancer

Drugs mentioned

• Aliqopa (copanlisib)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Thyroid Carcinoma, Thyroid Cancer | Phase 1 | Status: COMPLETED | Results posted: 2025-02-28